Abstract
Remaining a major healthcare concern with nearly 29 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus - 2 (SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, nine days prior to the pandemic declaration by WHO. Since then, more than 277 000 tests were carried out confirming a total of 1464 cases of COVID-19 in the country as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing sequencing campaign was started mid-March in collaboration with the local testing laboratories, with an ultimate goal in sequencing as much local viral isolates as possible, resulting in first full-length SARS-CoV-2 isolate genome sequences from the Baltics region being made publicly available in early April. With 133 viral isolates representing ∼9.1% of the total COVID-19 cases in the country being completely sequenced as of today, here we provide a first report on the genetic diversity of Latvian SARS-CoV-2 isolates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is funded by the Ministry of Education and Science, Republic of Latvia, project "Establishment of COVID-19 related biobank and integrated platform for research data in Latvia", project No. VPP-COVID-2020/1-0016, project "Multidisciplinary approach to monitor, mitigate and contain COVID19 and other future epidemics in Latvia", project No. VPP-COVID-2020/1-0008 and 04.06.2020. service contract No.23-11.3e/20/64 "Study on the epidemiology and phylogenesis of SARS-CoV-2 virus in Latvia" within the framework of ERDF project No.1.1.1.5 / 17 / I / 002 "Integrated national level measures for strengthening interest representations for research and development of Latvia as part of European Research Area".
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Central Medical Ethics Committee of Latvia (protocol No. 01-29.1/2429 and 01-29.1/1677).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All of the paper (including tables and figures) is updated with more recent data that changes some interpretations. Now, instead of 109 local isolates, we are describing 133 local isolates. One more author became involved in the analysis. NJ tree was swapped for a ML tree and MCC tree was annotated differently for a clearer representation of the results mentioned in the text.
Data Availability
The data used for this study are available either on GISAID or on request to the corresponding author.
